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Abstract
Background: Human papillomavirus (HPV) infection has been causally linked to six cancers, and many
disproportionately affect minorties. This study reports on the development and effectiveness of an intervention aimed
at increasing HPV vaccine uptake among African American and Hispanic pediatric patients in safety-net clinics.
Methods: Formative research, community engagement, and theory guided development of the intervention. A
clustered, non-randomized controlled pragmatic trial was conducted in four clinics providing healthcare for the
underserved in Tennessee, U.S., with two intervention sites and two usual care sites. Patients aged 9-18 years (N = 408)
and their mothers (N = 305) enrolled, with children clustered within families. The intervention consisted of two
provider/staff training sessions and provision of patient education materials, consisting of a video/flyer promoting HPV
vaccine. Medical records were reviewed before/after the initial visit and after 12 months.
Results: At the initial visit, provision of patient education materials and provider recommendation were higher at
intervention sites versus usual care sites, and receipt of HPV vaccine was higher at intervention sites (45.4% versus 32.
9%) but not significantly after adjusting for patient’s age and mother’s education. Provider recommendation, but not
education materials, increased the likelihood of vaccine receipt at the initial visit, although over one-third of
intervention mothers cited the flyer/video as motivating vaccination. Completion of the 3-dose series at follow-up was
lower in the intervention arm.
Conclusions: Future interventions should combine patient education, intensive provider/staff education, and patient
reminders. Research should compare patient education focusing on HPV vaccine only versus all adolescent vaccines.
Trial registration: Retrospectively registered with ClinicalTrials.gov NCT02808832, 9/12/16
Keywords: HPV vaccine, Hispanic, African American, Provider intervention, Safety-net clinics, Underserved
Background
Human papillomavirus (HPV) is a known cause for cer-
vical, vaginal, vulvar, penile, rectal, oropharyngeal and
anal cancers [1–3]. Racial and ethnic disparities exist in
incidence per 100,000 of HPV-associated cancers of the
cervix (black 9.2, and Hispanic 9.7 versus white 7.1), va-
gina (black 0.6 versus white 0.4), and penis (black 0.9
versus white 0.8) [4]. Although disparities are not
observed for incidence of oropharyngeal cancer, mortal-
ity for this HPV-associated cancer is higher for black
men (4.8 per 100,000) compared to white men (3.7 per
100,000) [5].
Immunization guidelines for HPV vaccine indicate
three doses for all 11-12 year-olds, starting as early as
age 9, with catch-up vaccination for females ages 13-26
and males ages 13-21 [4, 6]. Countries with national
school-based immunization programs have achieved
higher uptake of HPV vaccination than other countries
without school-based programs, including the U.S. [7–9].
In 2014, only 26.2% of 13-year old girls and 16.2% of
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13-year old boys in the U.S. had completed the 3-dose
HPV vaccine series, with the lowest female completion
rates in the state of Tennessee [10]. Hispanic females in
the U.S. had lower completion prior to 2013, and comple-
tion rates remain lower for African American females,
compared to non-Hispanic white females [10].
Without widespread school-based provision of HPV
vaccines in the U.S., healthcare provider recommenda-
tion is the strongest determinant of HPV vaccination
[11, 12]. Provider-focused intervention strategies include
training providers to make strong recommendations for
HPV vaccination at appropriate ages [13]. Parental lack
of knowledge, misinformation, and concerns about safety
are common barriers to HPV vaccination [11, 12].
Patient-focused intervention strategies include education
materials aimed to reduce vaccine hesitancy [13]. Very
few HPV vaccine interventions have used patient educa-
tion materials designed specifically for low-income
African Americans and Hispanics [14, 15]. Safety-net
clinics, providing primary care for underserved popula-
tions, could be leveraged to increase HPV vaccination
among low-income African American and Hispanic chil-
dren and reduce disparities in HPV-associated cancers.
The purpose of this study was to develop and evaluate
the effectiveness of an intervention that combined
provider-focused and patient-focused intervention strat-
egies, aimed to increase HPV vaccination among African
American and Hispanic pediatric patients ages 9-18 in
safety-net clinics via a pragmatic trial. We hypothesized
that patients at the intervention sites would be more
likely to report receiving patient education materials and
a provider recommendation (process measures) com-
pared to usual care. Further, we hypothesized that pa-
tients at intervention sites would be more likely to
receive the HPV vaccine at the initial visit and to
complete the three-dose vaccine series by 12-months




The study was conducted in four safety-net clinics in three
cities in Tennessee, U.S. The safety-net clinics provide
healthcare to low-income patients who are largely publicly
insured or uninsured. Across the clinics 83-94% of patients
lived in poverty, 34-61% were uninsured, and 13-50% were
on Medicaid or Children’s Health Insurance Program [16].
The racial/ethnic composition of the patient populations
varied, with 42-94% African American patients and 2-20%
Hispanic patients.
Formative research methods
Using a community-engaged approach and guided by
the Social Ecological Model (SEM) [17, 18], the study
team conducted formative research in collaboration
with clinic partners and a Community Advisory Board
(CAB) to develop an intervention that would be appro-
priate for use in safety-net clinics with racially- and
ethnically-diverse, underserved patient populations. We
used the SEM to examine individual, interpersonal
(family), and organizational factors influencing provider
behaviors and parental/patient decisions related to
HPV vaccination and cervical cancer screening. In-
depth interviews and focus groups were audio recorded
and transcribed. ATLAS.ti software [19] was used to
code emergent themes in each successive transcription
using the Qualitative Description method until reaching
saturation [20].
In-depth individual and group interviews (20-30 min)
were collected from a purposive sample of 41 healthcare
providers (physicians, physician assistants, and nurse
practitioners) providing pediatric or women’s health ser-
vices at the four clinic sites (additional details are in
press) [21]. Focus groups were conducted with a con-
venience sample of African American and Hispanic fe-
male adolescents aged 16-18 years and parents,
recruited from the clinic and local catchment areas.
Three focus groups were conducted with mothers (N =
16), two groups with fathers (N = 14), and three groups
with daughters (N = 15), with one each conducted in
Spanish. Focus groups ranged from 3 to 9 participants.
Older adolescent daughters were recruited because the
study started before HPV vaccination guidelines for
males were released in 2011 and was originally planned
to focus on simultaneous promotion of HPV vaccination
and cervical cancer screening, before guidelines were
changed to begin screening at age 21. Focus group par-
ticipants received $25 gift cards.
Intervention development
We formed a CAB composed of parents and adolescents
who participated in the focus groups (3 mothers, 3 fa-
thers and 3 daughters; one Hispanic and two African
American for each), 3 providers from the clinic sites and
3 community members from clinic catchment areas (one
per city). The CAB met three times to assist with devel-
opment of the intervention. In the first meeting, the
CAB reviewed the formative research findings and gave
input on the overall intervention goals, target popula-
tion, key messages, intervention strategies, and format of
the educational materials. Next, the study team met with
the medical directors and key staff from each clinic to
review the findings, share the CAB suggestions, and
gather their input on the intervention plan and content.
Additional file 1: Table S1 summarizes a selected list
of themes identified in analyses of the provider interview
and focus group transcriptions that informed the inter-
vention development. At the individual level, we
Sanderson et al. BMC Public Health  (2017) 17:158 Page 2 of 10
assessed the current knowledge of mothers, fathers, and
adolescent children about HPV vaccination and their
preferences for receiving health education information
and recommendations from their healthcare providers in
the safety-net clinics about HPV vaccination. This re-
vealed a number of barriers related to knowledge and at-
titudes that could be addressed in the content of the
educational materials, and it pointed to several preferred
options for format and mode of delivery for the CAB
and CHCs to consider. At the interpersonal level, we ex-
amined how healthcare providers, mothers, fathers, and
adolescent children made decisions about HPV vaccin-
ation together; overall, the mothers were the primary de-
cision makers, with input from the adolescent increasing
with age (results not shown). For this reason, we de-
signed the educational materials with the parents as the
primary audience, and the adolescents as the secondary
audience. In addition, at the interpersonal level we iden-
tified the preferences of parents and teens for the inter-
actions with their healthcare provider, which informed
the plan for intervention implementation during office
visits.
At the organizational level, the providers contributed
valuable information about how they carry out vaccine
discussions and recommendations during adolescent
visits. They also identified what types of patient education
materials supports would be feasible to implement in their
clinic’s patient flow and that they felt would help them be
able to make effective HPV vaccine recommendations to
their patients. The CAB and CHC leadership considered
all of these options suggested by the parents, adolescents,
and providers to plan the intervention components and
content. The resulting intervention included two compo-
nents: 1) provider and staff training, and 2) provision of
patient education materials (video and flyer).
In the second meeting, the CAB gave feedback on the
text, images, and layout of the flyer; the content and text
of the video script; and detailed plans for filming and
editing the video. Subsequently, part of the video was
filmed at one of the clinic sites, and some of the CAB
members appeared in the video. In the final meeting,
CAB members viewed the final educational materials
and gave input on recruitment and retention strategies.
In response to guideline changes and feedback from
the CAB and clinic partners, the intervention’s goal was
refocused to promote HPV vaccination in both female
and male adolescents (primary patient outcome), while
encouraging regular cervical cancer screening for the
mother accompanying them to the clinic. Modifications
to the intervention based on their input included the fol-
lowing: included males in the study and in patient edu-
cation materials; lowered the adolescent age range of
eligibility from 16-18 years to 9-18 years; tailored ver-
sions of the video by ethnicity, age and readiness for
HPV vaccination; and listed the six HPV-associated can-
cers in the education materials.
Intervention
Patient education materials
The team produced an educational video, with four 3-5
min versions specific to age range (preteen 9-12 years, no
mention of sexually-transmitted infection (STI); teen 13-18
years, mentioned STI) and readiness for HPV vaccination
for age (ready, briefer; undecided, full version). Additional
file 1: Table S2 summarizes the tailoring and topics covered
in each version. The English versions targeted African
Americans and the Spanish versions targeted Hispanics.
The videos included images of ethnically-diverse pre-
adolescents and adolescents, testimonials from an African
American or Hispanic parent and physician, and images of
an African American or Hispanic adolescent receiving the
vaccine.
The team produced a two-sided patient information
flyer in English and Spanish (Additional file 1: Exhibits
S1 and S2) with a list of possible questions to ask the
provider after watching the video, to help facilitate dis-
cussion. The back side listed brief highlights from the
video and space for recording return appointments for
the second/third vaccine doses and the Pap screening
recommendation for the mother.
Provider and staff training
The lead investigators delivered a one-hour training ses-
sion to the pediatric providers, nurses, and medical as-
sistants at the two intervention sites. The training
covered the following topics: factual information on
HPV-associated cancers, HPV vaccination and cervical
cancer screening guidelines; a summary of the formative
research findings and input from the CAB and CHC
leadership that guided tailoring of the intervention; how
to follow the intervention protocol; and suggestions on
what to say to patients based on the formative findings.
Approximately four months after launching the inter-
vention, the investigators delivered a refresher training.
A one-hour in-service training session on childhood
obesity was provided to the usual care sites.
Intervention protocol
After entering the exam room, the nurse/medical assist-
ant carried out standard patient intake, then gave the
flyer to the mother and asked her to answer the ques-
tions at the top (current HPV vaccination status, interest
in getting the HPV vaccine, and mother’s Pap screening
history). Based on the patient’s age and mother’s interest
in (readiness for) the vaccine, the nurse/medical assist-
ant played the appropriate version of the video for them
to watch while waiting for the provider and instructed
them to mark any questions they wanted to ask the
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provider. The providers were trained to make a strong
recommendation for the HPV vaccine, make an appro-
priate recommendation for the mother regarding Pap
screening, and answer any questions. If the patient re-
ceived the vaccine, the nurse was to record the target re-
turn dates on the flyer and instruct the mother to make
appointments at check out.
Pragmatic trial methods
Trial study design
In contrast to explanatory trials that aim to assess effi-
cacy under optimally-controlled conditions, pragmatic
trials are intended to test the effectiveness of interven-
tions in real-life conditions of routine clinical practice
[22]. We conducted a clustered, non-randomized con-
trolled pragmatic trial of an intervention in four safety-
net clinic sites. The sites were matched based on racial/
ethnic composition, then one site in each pair was
assigned to implement the intervention, and the other
two sites continued providing usual care. With more
than one eligible child able to enroll per family, the
pediatric patients were clustered within families. With
clinic-level assignment, it was not possible to blind data
collection and intervention staff. However, study partici-
pants were not told which study arm they were assigned
to. The study was reviewed and approved by the
Meharry Medical College and Erlanger Health System
Institutional Review Boards.
Study sample
Inclusion criteria for adolescents were being seen as a
patient at a study clinic, self-identified African Ameri-
can or Hispanic, male or female, aged 9-18 years, and
had received no HPV vaccine or received one and
was overdue for the second dose (three or more
months after the first dose). Exclusion criteria were
having two or more doses of HPV vaccine, mother or
female guardian (referred to as “mother” henceforth)
not accompanying the child, planning to move away
from the city within the next 12 months, not com-
pleting the baseline assessment prior to entering the
exam room, mother not providing or unable to give
consent, and child not giving assent. The intervention
primarily focused on initiation of the vaccine series,
while previous studies have demonstrated that a
major reason for non-completion is not being told
that the patient needed to return for two more doses
[12]. For that reason, included both non-vaccinated
patients and patients who received one but were
overdue for the second dose, since they may not have
been previously informed of the need for more doses.
Patients with two doses were excluded since they pre-
sumably would have already been aware of the need
for multiple doses. Sample size calculations indicated
that at least 176 participants per arm were needed to
detect a 15 percentage point difference in receipt of
HPV vaccine at the initial visit.
Recruitment
Participants were recruited into the trial between May 2013
and February 2015. Trained research assistants pre-
screened all appointments for each day in the clinic systems
and pre-screened walk-ins when feasible, to identify chil-
dren who were potentially eligible. The research assistants
attempted to approach each potentially-eligible family in
the waiting room to give a study flyer, request to screen for
eligibility, invite to enroll if eligible, obtain informed con-
sent and child assent, and sign medical record release
forms. In addition, to increase the volume of adolescent
visits, they called existing patients and distributed flyers at
health fairs to invite parents to schedule well visit appoint-
ments at the clinic, without mentioning the study.
Data collection
Mothers and children completed a pre-intervention
questionnaire before entering the exam room as well as
a post-visit questionnaire. Research assistants adminis-
tered the questionnaires on tablets using a secure, com-
puterized data management system called REDCap
(Research Electronic Data Capture) [23]. Twelve months
after the initial visit, research assistants contacted fam-
ilies to complete follow-up questionnaires via phone or
REDCap online survey, which were completed by May
2016. Mothers and adolescents received $25 and $15, re-
spectively, for completing the questionnaires each time.
Medical records were abstracted, including the clinic’s




Based on medical record abstractions, patients were
classified on two vaccination outcomes, 1) receipt of
HPV vaccine dose during the initial visit (Yes/No), and
2) HPV vaccine series completion (three or more doses)
by 12 months (Yes/No).
Intervention process measures
Mothers reported in the post-visit questionnaire whether
staff implemented the key intervention components,
with comparable questions for the usual care arm. 1) Pa-
tient Education Materials Provided: In the intervention
arm, mothers reported if the nurse/doctor gave them “a
card/flyer with facts and questions about the HPV vac-
cine” and showed them “a video about the HPV vaccine.”
This variable was coded as Yes if the mother reported
receiving at least one, and No if neither was received. In
the usual care arm, mothers were asked if the nurse/
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doctor gave them any printed materials about HPV vac-
cine (Yes/No); usual care sites did not view videos. 2)
Provider Recommended Vaccine: In both arms, mothers
were asked, “During your visit today, did the nurse/doc-
tor offer the HPV vaccine for your child?” (Yes/No).
Intervention fidelity index
In the intervention arm, an Intervention Fidelity Index
was constructed as a summed score of four items from
the post-visit questionnaire where mothers reported re-
ceiving the following intervention components, with the
sum ranging from 0 to 4: given patient education flyer,
shown patient education video, provider answered ques-
tions about HPV vaccine, and provider offered HPV vac-
cine for child.
Reasons for vaccination and non-vaccination
In the intervention arm only, mothers whose child re-
ceived the HPV vaccine during the visit were asked to
indicate the reasons why they chose to get it, and
mothers whose child did not receive the HPV vaccine
during the visit were asked to indicate the reasons why
they chose not to get it, selecting all that applied out of a
list of possible reasons (see Table 4). Next, they were
asked to indicate the most important reason. The reason
options for each were generated from our formative re-
search and previous studies. Two new categories were
coded from the write-in responses for “other reason” for
not vaccinating (“Doctor said to wait until older” and
“Not in stock/Pharmacy closed”).
Analysis
Statistical analysis was performed using SAS software,
Version 9.4 [24]. Chi-square was used to compare base-
line demographic characteristics between study arms.
Hypotheses were tested using intention-to-treat analyses.
Logistic regression analysis, accounting for clustering of
adolescents within families using generalized estimating
equations, was used to compare the intervention arm
versus the usual care arm on the two process measures
and the two vaccination outcomes.
Relative risks (RR) were reported both as crude RR
and adjusted RR, to assess the impact of adjusting for
relevant demographic characteristics. Next the process
measures were added to the logistic regression models
to estimate the effects of the process measures on vac-
cination outcomes. Within the intervention arm, the
Intervention Fidelity Index was cross-tabulated with Re-
ceipt of HPV Vaccine Dose at Initial Visit to examine
the impact of intervention fidelity on this outcome,
using Chi-square. Frequencies were generated for the
reasons for vaccine decisions in the intervention arm.
No imputation was used for missing data. All statistical
tests were two-sided using alpha < 0.05 to determine
significance, while noting effects with marginal signifi-
cance (alpha < 0.10) as suggestive of warranting further
research.
Results
Figure 1 outlines the flow of participants in the study,
yielding 405 children (303 families). As shown in Fig. 1
the refusal rate, based on children who either declined
to be screened or refused to participate, differed signifi-
cantly between the intervention arm (81/298 = 27.2%)
and the usual care arm (117/308 = 38.0%) (p = .005).
Medical records were successfully abstracted for 361
children (89.1%). Since one clinic site in the usual care
arm only successfully enrolled 17 children, resulting in
fewer than 15 medical abstractions, this site was ex-
cluded from the present analysis, which used medical
abstraction data. Including these cases does not change
the results reported below. Thus, the analytic sample in-
cluded 194 children (150 families) in the intervention
arm and 167 children (119 families) in the usual care
arm. Table 1 presents the baseline characteristics of the
participants by study arm. Mothers’ education (p = .03)
and child’s age (p < .01) significantly differed by study
arm, so these variables were included in adjusted
analyses.
Table 2 presents the process measures and patient out-
comes by study arm. Approximately 90% of patients in the
intervention arm received patient education materials
about HPV vaccine and a provider recommendation for
HPV vaccine during the initial visit, compared to 33.8%
(adjusted RR = 2.88, CI 2.06-4.01) and 50.3% (adjusted RR
= 1.70, CI 1.38-2.10), respectively, in the usual care arm.
In the intervention arm, 45.4% of patients received the
HPV vaccine during the initial visit, compared to 32.9% in
the usual care arm, which was not significant after adjust-
ing for mother’s education and child’s age (adjusted RR =
1.18, CI 0.87-1.60). Completion of the three-dose vaccine
series by 12-month follow-up was significantly lower in
the intervention arm versus usual care arm (12.4% versus
18.0%; adjusted RR = 0.50, CI = 0.29-0.88).
Table 3 reports multivariate models to assess the effect
of the process measures on vaccination outcomes.
Provision of patient education materials did not increase
the likelihood of vaccination at the initial visit or com-
pletion by follow-up. Patients who received a provider
recommendation during the initial visit were four times
more likely to be vaccinated (adjusted RR = 4.08, CI
2.17-7.66), but were not more likely to complete by
follow-up. The adjusted intervention effects in the multi-
variate models mirrored those in Table 2. Within the
intervention arm, the Intervention Fidelity Index sug-
gested a positive trend toward greater likelihood of vac-
cination at the initial visit, but it was only marginally
significant (p = 0.07) (See Additional file 1: Table S3).
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The most common mother-reported reasons for
accepting HPV vaccination at the initial clinic visit were
protecting child from cancer, preventing serious dis-
eases, video/flyer gave information needed, and protect-
ing child from HPV via future sexual partners (Table 4).
Three of these were also cited as the most important
reasons. Provider recommendation and provider answer-
ing questions were the next most common reasons.
The most common reasons for not receiving the vac-
cine included wanting more time to think about it, want-
ing more information, contraindication, child being too
young, concern about safety/side effects, and feeling the
child did not need it due to not being sexually active.
When asked to select the most important reason, the
most common were contraindication and concern about
safety/side effects.
Discussion
Based on the SEM and formative research with pro-
viders, parents, and adolescents, we used a community-
engaged approach to develop an intervention aimed to
increase HPV vaccination and evaluated its implementa-
tion in a pragmatic trial in safety-net clinics. Only two
previous studies have tested provider- or patient-focused
interventions designed for African American, Hispanic,
or low-income adolescent patients [14, 15].
Receipt of an HPV vaccine dose during the initial visit
was 12.5 percentage points higher in the intervention
versus usual care arm, but the difference was not signifi-
cant after adjusting for patient’s age and mother’s educa-
tion. In other words, part of the difference across arms
was due to a difference in patient characteristics. Ado-
lescent age has been positively associated with HPV vac-
cine uptake in numerous studies [11].
The intervention successfully improved the targeted
changes for providers and staff, with more frequent
provision of patient education materials and provider
recommendation versus usual care. In turn, provider
recommendation increased the likelihood of vaccine re-
ceipt at the initial visit, although provision of the patient
education materials did not. However, intervention arm
mothers reported the video/flyer as the third most
Fig. 1 Flow diagram of study participants
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common reason for obtaining the vaccine (38%), sug-
gesting they were influential for some parents in making
a decision to vaccinate.
Several interventions including provider training on
guidelines and strategies for increasing HPV vaccination
have had an effect in increasing uptake [25–27]. How-
ever, only one study has compared the impact of differ-
ent message framing approaches on HPV vaccination
outcomes [28]. Subsequent to designing the intervention
materials for this study, our team conducted another
study using a social marketing approach and found that
parents who viewed the HPV vaccine as unique from
other vaccines were more hesitant to get it for their chil-
dren [29]. Our findings suggested that parents may be
more willing to accept HPV vaccine when it is presented
as part of the overall adolescent vaccine platform that is
recommended for 11-12 year-olds (HPV, Tetanus-
diphtheria-pertussis, meningococcal vaccines), rather
than singling out HPV vaccine for focused education,
particularly for younger adolescents. Thus, our patient
education materials for the present study that focused
solely on the HPV vaccine could have had an unin-
tended effect of increasing hesitancy for some parents.
More research is needed to compare these different ap-
proaches and whether they should be tailored for differ-
ent age ranges. Even while bundling recommended
adolescent vaccines together, it is important for pro-
viders and educational materials to explain that HPV
vaccination does not eliminate the need for cervical can-
cer screening for females starting at age 21.
The intervention did not improve completion of the
three-dose series at 12-month follow up. The inter-
vention training encouraged providers to order follow-
up appointments and for staff to write the dates on
the patient flyer as a reminder. However, a patient re-
minder system was not employed to systematically
send reminders to parents about scheduled appoint-
ments. Several studies have shown patient reminders
to be effective in increasing series completion [30–32].
Future clinic-based interventions should consider in-
cluding automated reminder systems to enhance series
completion.
Limitations and challenges
The main study limitations were the small number of
clinics and patients and the non-random assignment
of clinics to study arms. The wide CIs argue for
Table 1 Demographic characteristics of participants with
medical record data by study arm
Intervention Usual care
Variable N (%) N (%) P-value
Mothers 150 Families 119 Families
Number of Enrolled Children 0.77
One 112 (74.7) 83 (69.8)
Two 30 (20.0) 27 (22.7)
Three 6 (4.0) 6 (5.0)
Four 2 (1.3) 3 (2.5)
Age 0.14
25-29 11 (7.9) 12 (10.8)
30-39 65 (46.8) 64 (57.7)
40-49 46 (33.1) 23 (20.7)
50 and older 17 (12.2) 12 (10.8)
Missing 11 8
Race/Ethnicity 0.85
African American 131 (87.3) 103 (86.6)
Hispanic 19 (12.7) 16 (13.4)
Family Monthly Income 0.11
Less than $1,000 41 (27.7) 31 (26.7)
$1,000-$1,999 68 (46.0) 39 (33.6)
$2,000 and over 27 (18.2) 32 (27.6)
Don’t Know 12 (8.1) 14 (12.1)
Missing 2 3
Educational Level 0.03
Less than high school 21 (14.3) 20 (17.1)
Completed high school 65 (44.2) 32 (27.4)
Some college or technical
school
42 (28.6) 39 (32.3)
Graduated from college
or more
19 (12.9) 26 (22.2)
Missing 3 2
Children 194 Children 167 Children
Gender 0.32
Boy 92 (47.4) 88 (52.7)
Girl 102 (52.6) 79 (47.3)
Age <0.01
9-12 100 (51.6) 118 (70.6)
13-15 47 (24.2) 35 (21.0)
16-18 47 (24.2) 14 (8.4)
Race/Ethnicity 0.82
African American 174 (89.7) 151 (90.4)
Hispanic 20 (10.3) 16 (9.6)
Insurance Status 0.08
None 36 (18.9) 17 (10.6)
Table 1 Demographic characteristics of participants with
medical record data by study arm (Continued)
Public 136 (71.6) 123 (76.9)
Private/Other 18 (9.5) 20 (12.5)
Don’t know/Missing 4 7
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cautious interpretation, and we did not have sufficient
power to examine interaction effects by gender or
ethnicity. Due to the nature of pragmatic trials being
conducted in real-life settings, randomization is not
always feasible, and the setting is not highly con-
trolled [22]. However, pragmatic trials such as these
contribute valuable information about the effective-
ness of interventions in contexts of routine clinical
practice. This study highlighted mothers’ education
and child’s age as important patient-population char-
acteristics that should be addressed in future studies,
either by tailoring interventions based on these char-
acteristics, by matching similar clinics prior to
randomization, or by controlling for these factors in
analyses. Although we attempted to match similar
clinics prior to randomization by including safety-net
clinics only, the influence of mother’s education ap-
pears to have persisted. The study experienced several
challenges in collaborating with safety-net clinics as
study sites with on-site research staff, including staff
turnover, frequent no-shows or late arrivals to ap-
pointments, and immunizations being out of stock or
unavailable due to temporarily suspension of Vaccines
for Children eligibility. Finally, while we gathered the
formative data and community-engaged input from
African American and Hispanic patients of safety-net
clinics and tailored the intervention materials to
match language and ethnic background, we did not
seek to identify or incorporate differences in deeper
cultural aspects such as beliefs, values, and norms
into the intervention. Future research may consider
the utility of a more extensive culturally-targeted
approach.
Conclusion
Safety-net clinics serve diverse, low-income patient
populatoins. This study demonstrated the feasibility of
training safety-net clinic staff and providers to utilize
tailored patient education materials developed through
a community-engaged process and offer the HPV vac-
cine to patients. However, implementation of these
changes did not lead to improved vaccine uptake or
completion compared to usual care after adjusting for
age and education. Future reseach should examine
more intensive provider/staff education, include patient
reminders, and compare the effectiveness of patient
education materials that focus solely on HPV vaccine
versus all adolescent vaccines.





Patient outcome: receipt of
HPV vaccine dose at initial visit
Patient outcome: completion of
3 doses at 12-month follow up
No Yes No Yes No Yes No Yes
Study Arm Nb (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Usual Care (UC) Arm 92 (66.2) 47 (33.8) 82 (49.7) 83 (50.3) 112 (67.1) 55 (32.9) 137 (82.0) 30 (18.0)
Intervention Arm 15 (7.9) 174 (92.1) 20 (10.8) 166 (89.2) 106 (54.6) 88 (45.4) 170 (87.6) 24 (12.4)
Crude RRc (95% CI)d 2.72 (1.97-3.76) 1.77 (1.44-2.19) 1.38 (1.03-1.85) 0.69 (0.40-1.17)
Adjusted RRe (95% CI)d 2.88 (2.06-4.01) 1.70 (1.38-2.10) 1.18 (0.87-1.60) 0.50 (0.29-0.88)
aPatient Education Materials included the intervention video and/or card in the intervention arm, or any printed materials about HPV vaccine in the usual
care arm
bN Number of children
cRR Relative risk
dCI Confidence interval
eRR Relative risk adjusted for mother’s educational level and child’s age
Table 3 Multivariate models of effects of intervention and process measures on HPV vaccination outcomes
Receipt of HPV vaccine dose at initial visit Completion of 3 doses at 12-month follow up
Adjusted RRb (95% CI)c Adjusted RRb (95% CI)c
Intervention (usual care-reference) 0.86 (0.61-1.21) 0.48 (0.25-0.92)
Patient education materials provideda 1.13 (0.76-1.68) 0.93 (0.49-1.78)
Provider recommended vaccine 4.08 (2.17-7.66) 1.44 (0.68-3.05)
Mother’s educational level 0.92 (0.78-1.08) 0.82 (0.61-1.09)
Child’s age 1.07 (1.02-1.12) 1.19 (1.09-1.30)
aPatient Education Materials included the intervention video and/or card in the intervention arm, or any printed materials about HPV vaccine in the usual
care arm
bRR relative risk adjusted for other variables in the model
cCI confidence interval
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Conclusions
This study demonstrated the feasibility of training
safety-net clinic staff and providers to utilize tailored pa-
tient education materials and recommend the HPV vac-
cine to patients. Future reseach should examine more
intensive provider/staff education, include patient re-
minders, and compare patient education materials that
focus on HPV vaccine versus all adolescent vaccines.
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Table 4 Mother-reported reasons for receiving or not receiving





Reasons for Receiving HPV
Vaccineb
n = 76 n = 71
Protect child from cancer 57.9 39.4
Vaccines important to prevent
serious diseases
44.7 11.3
Video and flyer gave information
needed
38.2 5.6
Protect child from HPV via future
sexual partners
35.5 18.3
Doctor/nurse recommended 31.6 0.0
Doctor/nurse answered questions 30.3 1.4
Better to be safe than sorry 27.6 5.6
Help my child live long and
happy life
25.0 5.6
Believe vaccine is safe 23.7 2.8
Don't want to regret it later
if child gets cancer
18.4 2.8
Cancer runs in my family 7.9 1.4
Vaccine has had no serious side
effects
7.9 0.0
Other reason/Don't know 2.6 5.6
Reasons for Not Receiving HPV
Vaccinec
n = 71 n = 59
Want more time to think about it 25.4 5.1
Want more information about
vaccine
18.3 6.8
Doctor said contraindicated due
to fever/illness
16.9 15.3
Child is too young for this vaccine 15.5 8.5
Worry about safety and side effects 15.5 15.3
Child doesn't need it because not
sexually active
15.5 10.2
Didn't have time today 9.9 10.2
Vaccine is too new 8.5 1.7
Doctor/nurse did not offer it today 7.0 5.1
May encourage child to become
sexually active
4.2 3.4
Doctor said to wait until older 4.2 5.1
Not in stock/Pharmacy closed 4.2 1.7
Want to discuss it with family
members first
2.8 1.7
Child doesn't need it because
risk of cancer is low
2.8 0.0
Never heard of vaccine and don't
know what it is
1.4 0.0
Don't trust drug companies 1.4 1.7
Child afraid of shots 0.0 0.0
0.0 0.0
Table 4 Mother-reported reasons for receiving or not receiving
the HPV vaccination at initial clinic visit, intervention arm only
(Continued)
Child doesn't need it because
already sexually active
Don’t trust my doctor/nurse 0.0 0.0
Costs too much 0.0 0.0
Other reason/Don’t know 11.3 8.5
Note: Wording from original questionnaire items has been abbreviated for
this table
a Mothers could select more than one response
bAmong mothers who completed the post-visit survey and whose child re-
ceived HPV vaccine at the initial visit
cAmong mothers who completed the post-visit survey and whose child did
not receive HPV vaccine at the initial visit
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